#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2102	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2210	183.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1640	1640	T	236	T,A	142,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2102	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2210	183.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1374	1374	C	267	C,T	168,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4186	23S	2890	2890	99.97	23S.l15.c4.ctg.1	3777	208.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2415	2415	C	167	C	107	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4186	23S	2890	2890	99.97	23S.l15.c4.ctg.1	3777	208.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2489	2489	A	165	A	109	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4186	23S	2890	2890	99.97	23S.l15.c4.ctg.1	3777	208.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	3041	3041	C	269	C	170	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	27	156	folP	852	852	100.0	folP.l15.c4.ctg.1	1473	20.1	1	SNP	p	R228S	0	.	.	682	684	CGC	941	943	CGC	21;21;21	C;G;C	15;16;13	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	510	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3353	28.8	1	SNP	p	S91F	0	.	.	271	273	TCC	484	486	TCC	32;32;32	T;C;C	20;20;20	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	510	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3353	28.8	1	SNP	p	D95G	0	.	.	283	285	GAC	496	498	GAC	31;31;31	G;A;C	19;19;20	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	510	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3353	28.8	1	SNP	p	D95N	0	.	.	283	285	GAC	496	498	GAC	31;31;31	G;A;C	19;19;20	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	166	mtrR	633	633	99.68	mtrR.l15.c4.ctg.1	1420	22.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	98	mtrR_promoter	250	250	99.2	mtrR_promoter.l15.c4.ctg.1	888	19.7	0	.	n	.	0	G33.	DEL	33	33	G	310	310	G	28	G	17	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	98	mtrR_promoter	250	250	99.2	mtrR_promoter.l15.c4.ctg.1	888	19.7	0	.	n	.	0	A208G	SNP	208	208	A	485	485	G	44	G	28	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	316	parC	2304	2304	99.78	parC.l15.c4.ctg.1	2728	21.4	1	SNP	p	D86N	0	.	.	256	258	GAC	473	475	GAC	25;25;27	G;A;C	16;14;16	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	316	parC	2304	2304	99.78	parC.l15.c4.ctg.1	2728	21.4	1	SNP	p	S88P	0	.	.	262	264	TCC	479	481	TCC	30;32;32	T;C;C	20;18;20	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	294	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2499	22.5	0	.	p	.	0	H611N	NONSYN	1831	1833	CAC	1979	1981	AAC	15;15;15	A;A;C	9;11;11	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	294	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2499	22.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1376	1378	GGC	22;22;22	G;G;C	14;13;13	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.1.001	penA.1.001	1	1	27	364	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2038	33.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1126	1128	GCA	48;48;48	G;C;A	30;28;30	penA.1.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	364	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2038	33.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1129	1131	ATC	50;50;50	A;T;C	31;29;29	penA.1.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	364	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2038	33.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1141	1143	GTG	48;48;48	G;T;G	31;29;31	penA.1.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	364	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2038	33.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1141	1143	GTG	48;48;48	G;T;G	31;29;31	penA.1.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	364	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2038	33.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1645	1647	ACC	17;17;16	A;C;C	9;11;10	penA.1.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	364	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2038	33.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1699	1701	GCG	13;13;13	G;C;G	9;9;9	penA.1.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	364	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2038	33.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1699	1701	GCG	13;13;13	G;C;G	9;9;9	penA.1.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	364	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2038	33.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1822	1824	GGC	8;8;8	G;G;C	4;4;4	penA.1.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	364	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2038	33.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1831	1833	GGC	10;10;10	G;G;C	5;5;5	penA.1.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	364	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2038	33.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1849	1851	CCG	10;10;10	C;C;G	5;5;5	penA.1.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	783	712	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3102	41.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	783	712	ponA	2397	569	95.09	ponA.l6.c4.ctg.2	740	0.7	0	.	p	.	0	Y226S	NONSYN	676	678	TAT	682	684	ACT	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	783	712	ponA	2397	569	95.09	ponA.l6.c4.ctg.2	740	0.7	0	.	p	.	0	R242L	NONSYN	724	726	CGC	634	636	GCT	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	783	712	ponA	2397	569	95.09	ponA.l6.c4.ctg.2	740	0.7	0	.	p	.	0	N247H	NONSYN	739	741	AAT	619	621	GCA	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	783	712	ponA	2397	569	95.09	ponA.l6.c4.ctg.2	740	0.7	0	.	p	.	0	D260G	NONSYN	778	780	GAT	580	582	CGA	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	783	712	ponA	2397	569	95.09	ponA.l6.c4.ctg.2	740	0.7	0	.	p	.	0	Y275C	NONSYN	823	825	TAT	535	537	ACA	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	783	712	ponA	2397	569	95.09	ponA.l6.c4.ctg.2	740	0.7	0	.	p	.	0	E276W	NONSYN	826	828	GAG	532	534	AAC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	783	712	ponA	2397	569	95.09	ponA.l6.c4.ctg.2	740	0.7	0	.	p	.	0	G279C	NONSYN	835	837	GGT	523	525	AAT	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	783	712	ponA	2397	569	95.09	ponA.l6.c4.ctg.2	740	0.7	0	.	p	.	0	E280V	NONSYN	838	840	GAA	520	522	CAC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	783	712	ponA	2397	569	95.09	ponA.l6.c4.ctg.2	740	0.7	0	.	p	.	0	T672N	NONSYN	2014	2016	ACT	347	349	TAA	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	783	712	ponA	2397	569	95.09	ponA.l6.c4.ctg.2	740	0.7	0	.	p	.	0	D679G	NONSYN	2035	2037	GAC	326	328	CGA	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	783	712	ponA	2397	569	95.09	ponA.l6.c4.ctg.2	740	0.7	0	.	p	.	0	R686G	NONSYN	2056	2058	CGT	305	307	CCC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	783	712	ponA	2397	569	95.09	ponA.l6.c4.ctg.2	740	0.7	0	.	p	.	0	A687G	NONSYN	2059	2061	GCC	302	304	CAC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	236	porA	1146	1146	99.83	porA.l6.c4.ctg.1	1949	22.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	553	553	C	15	C	8	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	224	porB1b	1035	1035	98.38	porB1b.l15.c4.ctg.1	1633	26.8	0	.	p	.	0	R143G	NONSYN	427	429	AGA	714	716	GGA	14;16;16	G;G;A	9;11;11	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	224	porB1b	1035	1035	98.38	porB1b.l15.c4.ctg.1	1633	26.8	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	918	918	T	19	T	13	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	224	porB1b	1035	1035	98.38	porB1b.l15.c4.ctg.1	1633	26.8	1	SNP	p	G120K	0	.	.	358	360	GGT	645	647	GGT	16;18;18	G;G;T	11;13;13	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	224	porB1b	1035	1035	98.38	porB1b.l15.c4.ctg.1	1633	26.8	1	SNP	p	A121N	0	.	.	361	363	GCC	648	650	GCC	18;18;18	G;C;C	12;13;13	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	224	porB1b	1035	1035	98.38	porB1b.l15.c4.ctg.1	1633	26.8	1	SNP	p	A121D	0	.	.	361	363	GCC	648	650	GCC	18;18;18	G;C;C	12;13;13	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	888	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5121	32.7	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2037	2039	CAT	29;29;29	C;A;T	20;19;19	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	74	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1149	13.0	1	SNP	p	V57M	1	.	.	169	171	ATG	663	665	ATG	28;27;28	A;T;G	20;19;20	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
